<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532064</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0921</org_study_id>
    <secondary_id>NCI-2018-02471</secondary_id>
    <secondary_id>2006-0921</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT00532064</nct_id>
  </id_info>
  <brief_title>Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy</brief_title>
  <official_title>Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well cardiac biomarkers work in the early detection of cardiotoxicity
      in patients receiving sunitinib malate or sorafenib chemotherapy. Some chemotherapies are
      known to cause damage to heart muscle cells, resulting in heart failure. Often, the damage is
      not detected until heart failure has already occurred. Testing for cardiac biomarkers, such
      as troponin I and/or T and B-type natriuretic peptide (BNP), may be useful in detecting heart
      damage earlier than other tests currently performed (such as echocardiogram and
      electrocardiogram).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if specific biomarkers (troponin I and B-type natriuretic peptide [BNP])
      detect cardiotoxicity earlier than standard clinical means in patients receiving sunitinib
      malate (SU11248) or sorafenib chemotherapy.

      SECONDARY OBJECTIVES:

      I. To prospectively evaluate the incidence and severity of cardiac toxicity related to
      sunitinib or sorafenib during chemotherapy.

      OUTLINE:

      Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2
      weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated per PI's request
  </why_stopped>
  <start_date type="Actual">September 12, 2007</start_date>
  <completion_date type="Actual">May 2, 2018</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of each biomarker for detecting cardiotoxicity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will estimate with exact 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of each biomarker for detecting cardiotoxicity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will estimate with exact 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiotoxicity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will use the methods of Gooley, et al (1999) to estimate the cumulative incidence of cardiotoxicity while considering deaths from other causes as a competing risk. Will estimate the cumulative incidence of cardiotoxicity while stratifying by common risk factors (one at a time). Will use mixed linear models to model the biomarker levels over time, accounting for the correlation between biomarker levels within patient. Will use logistic regression to model the log odds of cardiotoxicity as a function of common risk factors for cardiotoxicity. Will also include the duration of chemotherapy use and the MD Anderson Symptom Inventory - Heart Failure (MDASI-HF) score as a potential prognostic factor for cardiotoxicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD Anderson Symptom Inventory - Heart Failure (MDASI-HF) score</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will summarize the MD Anderson Symptom Inventory - Heart Failure (MDASI-HF) score over time with descriptive statistics and boxplots.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">55</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Ancillary-correlative (biospecimen collection)</arm_group_label>
    <description>Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood</description>
    <arm_group_label>Ancillary-correlative (biospecimen collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Ancillary-correlative (biospecimen collection)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MDACC Cancer Participants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age 18-85 years

          -  Starting a new course of chemotherapy at MD Anderson Cancer Center that includes
             sunitinib or sorafenib

          -  Has a life expectancy of greater than 6 months

        Exclusion Criteria:

          -  Unstable angina within the last 3 months

          -  Myocardial infarction within the last 3 months

          -  Left ventricular ejection fraction (LVEF) less than 40%

          -  Decompensated heart failure (HF) in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie Mouhayar</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 18, 2007</study_first_submitted>
  <study_first_submitted_qc>September 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2007</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

